Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gabizon

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Cancer Research Communications|June 26, 2026
A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancerAlberto A Gabizon, Hadar Goldvaser, Adar Yaacov, et al.
Seminars in Oncology|February 19, 2005
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancerNicholas J Robert, Charles L Vogel, I Craig Henderson, et al.
Seminars in Oncology|February 19, 2005
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trialsDavid S Alberts, Franco M Muggia, James Carmichael, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Cancer Research Communications|June 26, 2026
A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancerAlberto A Gabizon, Hadar Goldvaser, Adar Yaacov, et al.
Seminars in Oncology|February 19, 2005
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancerNicholas J Robert, Charles L Vogel, I Craig Henderson, et al.
Seminars in Oncology|February 19, 2005
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trialsDavid S Alberts, Franco M Muggia, James Carmichael, et al.
Pageof 9